Nuvectis Pharma has commenced the Phase I clinical trial of an oral drug candidate, NXP800, in subjects with advanced cancers.

An inhibitor of pathway regulatory by heat shock factor 1 (HSF1) transcription factor, the drug candidate was discovered at The Institute of Cancer Research (ICR), London in the UK.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nuvectis licenced the exclusive global rights for drug development and marketing from oncology investment fund, CRT Pioneer Fund.

The Nuvectis-sponsored trial plans to dose the first subjects with the novel drug soon.

It will have two parts, a Phase Ia dose-escalation portion and a Phase Ib dose-expansion segment.

Phase Ia part will assess the safety and tolerability of NXP800 in advanced solid tumour patients to detect a dose and dosing regimen for Phase Ib.

In the Phase Ib segment, the safety and anti-tumour activity of the drug will be analysed in biomarker-selected subjects, in clear cell ovarian cancer in the initial stage and endometrioid ovarian carcinoma.

The company plans to carry out Phase Ia trial in the UK while Phase Ib will be conducted in the US and the UK.

Furthermore, an ICR team will evaluate the molecular effects of NXP800 and its processing by the body. Biomarkers assessed in this approach will generate a ‘pharmacological audit trail’ of the behaviour of the oral drug.

ICR London chief executive professor Kristian Helin said: “We’re delighted to see this innovative inhibitor of HSF1 signalling enter its first clinical trial.

“NXP800 is the 12th ICR-discovered drug we’ve taken into clinical trials for cancer patients since 2005, in collaboration with industrial partners like Nuvectis.”

In August last year, ICR and Nuvectis announced plans to start a Phase I trial of NXP800 in individuals with advanced cancer.